374 related articles for article (PubMed ID: 9010834)
1. Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment.
Zacharieva S; Stoeva I; Andreeva M; Kalinov K; Matrozov P; Andonova K
Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):593-7. PubMed ID: 9010834
[TBL] [Abstract][Full Text] [Related]
2. Plasma aldosterone response to metoclopramide in patients with Cushing's disease.
Zacharieva S; Stoeva I; Matrozov P; Andonova K
Exp Clin Endocrinol; 1993; 101(3):138-43. PubMed ID: 8223981
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
4. [Role of hypothalamo-hypophyseal-adrenal axis in the pathogenesis of arterial hypertension in patients with prolactinoma of the anterior lobe of the hypophysis].
Mychka VB; Chazova IE; Dmitriev VV; Masenko VP
Ter Arkh; 2000; 72(9):10-3. PubMed ID: 11076407
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic effects on kidney function and responsiveness of aldosterone, plasma renin activity, prolactin, catecholamines, and blood pressure to stimulation in patients with prolactinoma. Comparison of the efficacy of pergolide and bromocriptine therapy.
Jungmann E; Haak T; Althoff PH; Fassbinder W; Schöffling K
Arzneimittelforschung; 1988 Feb; 38(2):296-300. PubMed ID: 3285838
[TBL] [Abstract][Full Text] [Related]
6. A patient with a prolactinoma associated with an aldosterone producing adrenal adenoma: differences in dopaminergic regulation of PRL and aldosterone secretion.
Demura R; Naruse M; Isawa M; Onoda N; Naruse K; Yamakado M; Demura H
Endocrinol Jpn; 1992 Apr; 39(2):169-76. PubMed ID: 1396349
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.
Carey RM; Thorner MO; Ortt EM
J Clin Invest; 1980 Jul; 66(1):10-8. PubMed ID: 7400305
[TBL] [Abstract][Full Text] [Related]
8. Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia--a case report with a review of the literature.
Konopelska S; Quinkler M; Strasburger CJ; Ventz M
J Clin Psychopharmacol; 2008 Feb; 28(1):120-2. PubMed ID: 18204364
[No Abstract] [Full Text] [Related]
9. Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy.
Bronstein MD
Nat Clin Pract Endocrinol Metab; 2006 Mar; 2(3):130-1. PubMed ID: 16932269
[No Abstract] [Full Text] [Related]
10. High prolactin level.
Piketty ML; Nataf F; Dilouya A; Roux FX
J Neurosurg; 2000 Feb; 92(2):368-9. PubMed ID: 10659034
[No Abstract] [Full Text] [Related]
11. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
12. [Macroprolactinoma resistant to bromocriptine].
López-Espinosa E; Ayala AR; Grimaldo J; Kunhardt J; Villanueva C
Arch Invest Med (Mex); 1989; 20(1):1-8. PubMed ID: 2669670
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of prolactinoma with a new dopamine agonist].
Svoboda T; Luger A; Knosp E; Geyer G
Dtsch Med Wochenschr; 1991 Aug; 116(33):1224-7. PubMed ID: 1678695
[TBL] [Abstract][Full Text] [Related]
14. Serum aldosterone response to metoclopramide in normal subjects and acromegalic patients.
Zacharieva S; Stoeva I; Matrozov P; Andonova K
Exp Clin Endocrinol; 1990 Aug; 95(3):331-8. PubMed ID: 2245821
[TBL] [Abstract][Full Text] [Related]
15. Normal growth and pubertal development during bromocriptine therapy in two patients with prolactinoma.
Kamel N; Uysal AR; Cesur V; Erdoğan G; Başkal N
Endocr J; 1995 Aug; 42(4):581-6. PubMed ID: 8556068
[TBL] [Abstract][Full Text] [Related]
16. Giant invasive prolactinoma: a case report and review of nine further cases.
Davis JR; Sheppard MC; Heath DA
Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
[TBL] [Abstract][Full Text] [Related]
17. Evidence for increased endogenous dopaminergic inhibition of aldosterone secretion in prolactinoma.
Jungmann E; Schwedes U; Althoff PH; Rosak C; Schöffling K
Horm Metab Res; 1986 Oct; 18(10):704-5. PubMed ID: 3781476
[TBL] [Abstract][Full Text] [Related]
18. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
Nickelsen T; Jungmann E; Althoff P; Schumm-Draeger PM; Usadel KH
Arzneimittelforschung; 1993 Apr; 43(4):421-5. PubMed ID: 8098604
[TBL] [Abstract][Full Text] [Related]
19. [Effects of therapy and pregnancy on hyperprolactemia caused by a pituitary adenoma. A clinical case].
Pasinetti E; Schivardi MR; Falsetti L; Gastaldi A
Minerva Ginecol; 1989 Mar; 41(3):157-60. PubMed ID: 2666885
[TBL] [Abstract][Full Text] [Related]
20. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
